THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 126 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2021. The put-call ratio across all filers is 0.56 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $311,000 | -50.9% | 30,700 | -56.1% | 0.02% | -60.4% |
Q2 2022 | $633,000 | +219.7% | 69,890 | +237.1% | 0.05% | +269.2% |
Q1 2022 | $198,000 | -43.6% | 20,730 | -34.7% | 0.01% | -70.5% |
Q4 2021 | $351,000 | +158.1% | 31,730 | +72.6% | 0.04% | +144.4% |
Q3 2021 | $136,000 | – | 18,380 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Link Fund Solutions Ltd | 5,251,349 | $135,459,000 | 69.86% |
Chescapmanager LLC | 949,006 | $24,570,000 | 3.61% |
Baupost Group | 9,309,168 | $241,014,000 | 2.66% |
Rock Springs Capital Management LP | 655,200 | $16,963,000 | 0.54% |
Rubric Capital Management LP | 173,400 | $4,489,000 | 0.51% |
Newtyn Management, LLC | 173,300 | $4,487,000 | 0.41% |
NJ State Employees Deferred Compensation Plan | 38,142 | $988,000 | 0.17% |
King Wealth Management Group | 22,500 | $583,000 | 0.15% |
Virtus ETF Advisers LLC | 29,216 | $756,000 | 0.12% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 452,615 | $11,718,000 | 0.12% |